Skip to main content

Table 5 Adverse Reactions Categorized by Indication

From: 2015 Update on Acute Adverse Reactions to Gadolinium based Contrast Agents in Cardiovascular MR. Large Multi-National and Multi-Ethnical Population Experience With 37788 Patients From the EuroCMR Registry

 

All

RS CAD

MYO/CMP

Viability

Severe

2/37788 (0,01%)

2/18840 (0,01%)

0/14106 (0%)

0/4037 (0%)

Mild

43/37788 (0,11%)

7/18840 (0,04%)

22/14106 (0,16%)

9/4037 (0,22%)

All

45/37788 (0,12%)

9/18840 (0,05%)

22/14106 (0,16%)

9/4037 (0,22%)

  1. RS CAD, risk stratification in suspected coronary artery disease; MYO/CMP, work-up of suspected myocarditis or cardiomyopathy; Viability, work-up of myocardial viability in known coronary artery disease. See references 1- 4 for details